Cargando…
Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
There remains an unmet need for effective, well-tolerated treatment options in advanced non-small cell lung cancer (NSCLC) to alleviate the disease burden for a broad selection of patients. Nintedanib is a potent, oral, triple angiokinase inhibitor of vascular endothelial growth factor, fibroblast g...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494183/ https://www.ncbi.nlm.nih.gov/pubmed/26170616 http://dx.doi.org/10.2147/BTT.S57356 |
_version_ | 1782380039482900480 |
---|---|
author | Reck, Martin Mellemgaard, Anders |
author_facet | Reck, Martin Mellemgaard, Anders |
author_sort | Reck, Martin |
collection | PubMed |
description | There remains an unmet need for effective, well-tolerated treatment options in advanced non-small cell lung cancer (NSCLC) to alleviate the disease burden for a broad selection of patients. Nintedanib is a potent, oral, triple angiokinase inhibitor of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor, and was recently approved in Europe for use in combination with docetaxel for the treatment of adults with locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma tumor histology, following first-line chemotherapy. Nintedanib has been investigated extensively in preclinical research and in a number of clinical studies, the most important of which was the Phase III LUME-Lung 1 study, which investigated nintedanib in combination with docetaxel in patients with advanced NSCLC after failure of first-line chemotherapy. In this study, which led to the approval of nintedanib, addition of nintedanib to docetaxel significantly improved overall survival in patients with adenocarcinoma histology. Nintedanib demonstrated a manageable safety profile in combination with docetaxel. This review focuses on the clinical experience with nintedanib in NSCLC and discusses the clinical potential of this agent for use in combination with chemotherapy. |
format | Online Article Text |
id | pubmed-4494183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44941832015-07-13 Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib Reck, Martin Mellemgaard, Anders Biologics Review There remains an unmet need for effective, well-tolerated treatment options in advanced non-small cell lung cancer (NSCLC) to alleviate the disease burden for a broad selection of patients. Nintedanib is a potent, oral, triple angiokinase inhibitor of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor, and was recently approved in Europe for use in combination with docetaxel for the treatment of adults with locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma tumor histology, following first-line chemotherapy. Nintedanib has been investigated extensively in preclinical research and in a number of clinical studies, the most important of which was the Phase III LUME-Lung 1 study, which investigated nintedanib in combination with docetaxel in patients with advanced NSCLC after failure of first-line chemotherapy. In this study, which led to the approval of nintedanib, addition of nintedanib to docetaxel significantly improved overall survival in patients with adenocarcinoma histology. Nintedanib demonstrated a manageable safety profile in combination with docetaxel. This review focuses on the clinical experience with nintedanib in NSCLC and discusses the clinical potential of this agent for use in combination with chemotherapy. Dove Medical Press 2015-07-01 /pmc/articles/PMC4494183/ /pubmed/26170616 http://dx.doi.org/10.2147/BTT.S57356 Text en © 2015 Reck and Mellemgaard. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Reck, Martin Mellemgaard, Anders Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib |
title | Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib |
title_full | Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib |
title_fullStr | Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib |
title_full_unstemmed | Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib |
title_short | Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib |
title_sort | emerging treatments and combinations in the management of nsclc: clinical potential of nintedanib |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494183/ https://www.ncbi.nlm.nih.gov/pubmed/26170616 http://dx.doi.org/10.2147/BTT.S57356 |
work_keys_str_mv | AT reckmartin emergingtreatmentsandcombinationsinthemanagementofnsclcclinicalpotentialofnintedanib AT mellemgaardanders emergingtreatmentsandcombinationsinthemanagementofnsclcclinicalpotentialofnintedanib |